Abstract: Information on the safety of paternal use of medications prior to the time of conception is limited, and there is little available evidence regarding possible adverse effects of paternal use of systemic corticosteroids (SCS). In this cohort study, based on nationwide data, we examined the association between paternal use of SCS prior to conception and adverse birth outcome. The study includes data from all singletons born in Denmark from 1 January 1997 through 2013 (N = 1,013,994). Children fathered by men who redeemed a prescription of SCS within 3 months before conception (N = 2380) constituted the exposed groups. The outcome was congenital abnormalities (CAs), pre-term birth and small-for-gestational age (SGA). We adjusted for co-variates in multi-level logistic regression analyses. The adjusted odds ratios for pre-term birth and SGA were 0.81 (95% CI: 0.55-1.21) and 1.06 (95% CI: 0.68-1.64), respectively. The adjusted odds ratios for CAs were 1.08 (95% CI: 0.87-1.40) in children fathered by men who redeemed one prescription within 3 months before conception and 1.33 (95% CI: 0.99-1.79) in children fathered by men who redeemed two or more prescriptions. This study is the largest to date examining the effect of paternal use of SCS prior to conception on birth outcome. We found no significantly increased risk of pre-term birth or SGA. In children of fathers who redeemed at least two prescriptions of SCS within 3 months before conception, we found an increased risk of CAs, though not statistically significant. The types of CAs did not show a distinct pattern.
The use of medications during the period of conception and pregnancy is of great concern for both patients and physicians. The safety of medical treatment during this time is an extremely important issue because a very large proportion of patients with chronic diseases, for example chronic inflammatory bowel disease, rheumatologic diseases and connective tissue diseases, require continuous medical treatment during the fertile years. Most of our knowledge about possible adverse effects on the foetus has focused on the consequences of medical treatment of pregnant women, and we do have some evidence on the safety of azathioprine/6-mercaptopurine, corticosteroids and anti-TNF medications taken during conception and/or pregnancy. Compared to the existing literature on the associations between maternal medication use during pregnancy and birth outcome, the available data on possible adverse effects after paternal use of medication around the time of conception are very sparse [1, 2] . A recently published study by Valer et al. [3] reports that men with Crohn's disease tend to have poor semen quality. Other studies have focused on the impact of specific medications on sperm abnormalities [4] [5] [6] [7] , and apart from case reports, only very few studies have focused on the clinical impact, in terms of birth outcome, of paternal medications taken around the time of conception. For instance, a few controlled studies examined the impact of paternal use of azathioprine/6-mercaptopurine within 3 months before conception [8] [9] [10] , one study examined the impact of paternal use of anti-TNF-a agents [11] , and one study looked at paternal prescription data for antirheumatic drugs with a focus on congenital abnormalities (CAs) [12] .
Systemic corticosteroids (SCS) are used for various diseases where the aim is to achieve immunosuppression, and the question about the safety of paternal use of SCS around the time of conception is thus highly relevant for fathers with conditions such as chronic inflammatory bowel disease, rheumatic diseases, connective tissue diseases and a variety of other illnesses.
Potential mechanisms of corticosteroid toxicity have been demonstrated in animal studies. In rats, corticosterone treatment significantly decreased epididymal lipids [13] . In rats, exogenous administration of corticosterone produced reversible effects on implant count and litter size of female rats mated to these males. These authors suggest that the direct transfer of corticosterone itself may have interfered with embryonic viability [14] . Another study in rats demonstrated that corticosteroids may inhibit apoptosis of damaged sperm cells and/or prevent pathological excessive apoptosis which results in oligospermia [15] .
In adult men, corticosteroids excess may be associated with suppressed levels of plasma and urinary testosterone, decreased libido and impaired spermatogenesis [7, 16] . Increased endogenous cortisol levels induced by overtraining Author for correspondence: Michael Due Larsen, Center for Clinical Epidemiology, Odense University Hospital, Kløvervaenget 30, DK-5000, Odense C, Denmark (e-mail michael.due.larsen@rsyd.dk).
in men decreased testosterone levels and sperm counts [17] . In addition, there is preliminary evidence of the effects of poor semen quality on birth outcome; increased paternal age in human beings can increase the risk of pre-term birth, probably through a negative impact on sperm parameters [18] .
At this point, the independent effect of SCS therapy on congenital abnormalities (CA) and other important birth outcome is not known [12, 19] , and, so far, no recommendations for fathers have been made due to lack of data [20] . We therefore examined the association between paternal use of SCS prior to conception and adverse birth outcome, based on available data from Danish national registries during a study period of 17 years.
Methods
Study setting. In Denmark (population approximately 5.5 million people, >90% Caucasians), all citizens have free and equal access to a tax-supported health care system, and its uniform organization allowed us to use a population-based study design. In this study, nationwide Danish health registries, that is, the Danish National Patient Registry (NPR) [21] , the Danish Medical Birth Registry (MBR) [22, 23] , the Central Personal Registration system (CPR) [24] , and the nationwide prescription database (NPD) [25] , were linked using the unique civil registration number. Since 1968, this unique number has been assigned to all Danish residents at birth from the CPR [24] , and data from all sources were unambiguously linked on an individual level using the civil registration number.
Data sources. The NPR includes records of all discharges from Danish hospitals since 1977 and all outpatient visits since 1994. Information in the NPR includes patients' civil registration numbers, hospital, department, date of admission and discharge, procedures performed, up to 20 discharge diagnoses based on the International Classification of Diseases (ICD-8 before 1994 and ICD-10 from 1994 onward; ICD 9 was never used in Denmark), and information on type of paternal underlying diseases.
Since 1973, the MBR has recorded information on all births in Denmark, and the MBR includes data on the mother, the father, pregnancy-related information and information on birth outcome. Data from the CPR provided information on the civil registration number, death and immigration. Since 1 January 1995, data on outpatient drug prescriptions are available from the NPD maintained by the Danish Medicines Agency [26] . All pharmacies in Denmark are equipped with a computerized accounting system that sends key data on outpatient drug prescriptions directly to the NPD. The data transferred to the prescription database include the patient's civil registration number, the type of drug prescribed according to the anatomical therapeutical chemical (ATC) classification system and the date of filed prescription. Using civil registration numbers, it is thus possible to obtain the prescription history of each person, and in this case, information according to use of SCS was retrieved. The NPD does not include data on sales of over-the-counter drugs, but SCS are available only by prescription in Denmark.
Study population, exposed and unexposed cohorts. We included nationwide data on all women who, between 1 January 1997 and 31 December 2013 had a live-born singleton child in Denmark, and from the MBR, we identified persons registered as fathers to these singleton children. We used reimbursement of a prescription of SCS as a proxy for fathers' use of SCS, and these fathers were categorized according to filled prescriptions for use of SCS within 3 months before the date of the conception (exposed cohort) (Oral use of ATC codes: H02AB02 dexamethasone, H02AB04 methylprednisolone, H02AB06 prednisolone, H02AB07 prednisone, H02AB09 hydrocortisone). SCS are prescribed for both long-term and periodic use in various doses and pack sizes, and to examine the impact of the level of SCS exposure, we subdivided children in the exposed cohort into (i) 'current users 1' (children fathered by men with one redeemed prescription 90-0 days before conception) and (ii) 'current users 2' (children fathered by men with two or more redeemed prescription 90-0 days before conception). In our analyses, 'former users' were defined as children fathered by men who did not use SCS within 3 months prior to conception but they had at least one prescription of SCS in the period of 365-90 days before the date of conception. The 'non-users' were children of fathers who had not redeemed prescriptions of SCS within 1 year before the date of conception. The fathers in exposed and unexposed cohorts were allowed to be treated with drugs other than SCS. The date of conception was based on information from the ultrasound-measured gestational age registered in the MBR, and all Danish pregnant women are provided ultrasound examinations since 2005. Before 2005, time of conception was estimated by clinical assessment or ultrasound examinations. Ultrasound examinations were available and in most hospital sites since 2001.
Birth outcome. The birth outcome was CAs, pre-term birth (birth before 37 completed weeks of pregnancy) and birthweight as smallfor-gestational age (SGA), that is below the mean À2 S.D. according to gestational age and sex [26] . This outcome was identified in the MBR and information on CAs was obtained from the NPR (ICD-10: Q0.0-Q9.9). Diagnoses of undescended testis (ICD-10: Q5.5) and dislocations of the hip (ICD-10: Q6.5) were excluded due to low validity of registration [27] . The recording of CAs covered malformations recognized within the first year of life.
Information on possible confounders. From the MBR, we obtained information on age of the father and mother at the time of delivery, parity, gender of the child as well as and maternal smoking and maternal body mass index (BMI) as recorded at the first antenatal visit in early pregnancy.
Statistical analysis. Contingency tables were constructed for the main study variables according to the exposed and unexposed cohorts. We used mixed-effect multi-level logistic regression analyses to compute crude and adjusted relative risk estimates (prevalence odds ratio [OR] with 95% confidence intervals [95% CI]) for adverse birth outcome after paternal use of SCS prior to conception relative to no paternal use of SCS prior to conception. Using a mixed-effect model, we accounted for the random effects that stem from multiple children born by the same woman. Adjustment was made for mother's and father's age, BMI of the mother, parity, maternal smoking in pregnancy and gender of the child.
All calculations were performed using STATA Release 14.0 (StataCorp, College Station, TX, USA).
Approvals and ethics. The study was approved by the Danish Data Protection Agency (j.nr. 2014-41-3466). According to Danish law, no ethical approvals of register-based studies are necessary.
Results
A total of 2380 singleton children were fathered by men who filled at least one prescription with SCS within 3 months before conception ('current users 1' = 1558 and 'current users 2' = 822). A total of 1,011,614 children were fathered by men who had filled no prescriptions of SCS within 3 months before conception ('non-users' = 1,006,672 and 'former users' = 4942). The basic characteristics were very similar between the exposed and unexposed cohorts according to mother's and father's age, maternal BMI, maternal smoking and parity (table 1). The most frequently used SCS were prednisolone and prednisone covering 81% and 12% of registered prescriptions. Among fathers exposed to SCS, the three most prevalent types of underlying paternal diseases were (i) asthma/allergy (26.7%), (ii) inflammatory bowel disease (14.4%) and (iii) rheumatologic diseases (10.0%; table 1). In 45.2% of the men treated with SCS prior to conception, the indication for SCS could not be identified in the available registers. In the exposed group, we found four stillborn children 0.26%, whereas 17 (0.35%) were found in the group of 'former users' of SCS.
The adjusted OR for pre-term birth did not show a trend across levels of exposure (table 2) , that is neither one redeemed prescription nor ≥2 redeemed prescriptions in the period of 3 months before conception was associated with a significant increased risk, aOR = 1.05 (95% CI: 0.80-1.37), and 0.81 (95% CI: 0.55-1.21), respectively. Also, the adjusted OR for SGA did not show a trend across levels of exposure (table 2) , and neither one redeemed prescription or ≥2 redeemed prescriptions within 3 months before conception was associated with a statistically significant increased risk, aOR = 1.13 (95% CI: 0.83-1.56) and 1.06 (95% CI: 0.68-1.64), respectively. Regarding CAs, the adjusted OR was 1.08 (95% CI: 0.86-1.36) for children fathered by men with one redeemed prescription 3 months before conception, and the adjusted OR was 1.33 (95% CI: 0.99-1.79) for children fathered by men who redeemed ≥2 prescriptions within 3 months before conception. The specific types of CAs in the children of fathers exposed to SCS within 3 months before conception, and among unexposed, are given in table 3. The distribution of CAs according to different organ groups of CAs did not show any distinct pattern associated with SCS exposure. 4 Inflammatory rheumatic diseases, spondylopathies, inflammatory polyarthritis/psoriasis. 5 Rheumatic diseases, connective tissue including, for example polymyalgia, Sj€ ogren's syndrome. 6 Other diseases where SCS is given for a variety of indications: for example ganglion.
Discussion
This is the largest and most comprehensive study to date on the effect of SCS used by men prior to conception on adverse birth outcome, and the overall results are reassuring. Our study showed that the children of men who redeemed one prescription of SCS prior to conception had no significantly increased risk of CAs, SGA or pre-term birth compared to children of men who did not use SCS. The analyses of patients who redeemed at least two prescriptions within 3 months prior to conception strengthen our conclusion that use of SCS prior to conception was not associated with an increased risk of SGA or pre-term birth. There was an increased OR of 1.33 for CAs in fathers who had redeemed two or more prescriptions of SCS 3 months prior to conception, although the result was not statistically significant. For ethical reasons, randomized trials are not conducted to evaluate the safety of drugs like SCS during pregnancy and conception. Therefore, we must base our clinical decisions on evidence from observational studies like this that might be vulnerable to bias, confounding and problems with statistical precision. Although this study is the largest to date on birth outcome among fathers exposed to SCS prior to conception, considerations of the precision of our risk estimates are relevant due to the low prevalence of adverse outcome. This is particularly relevant for CAs, because no known teratogens increase the risk of all CAs, but rather tend to increase the rates of selected CAs. Under ideal circumstances, the risk of specific CAs should be examined instead of overall rates like this study, but examining specific CAs would have a major impact on the sample size requirements. Therefore, in this study, we did not have the opportunity to examine the risk of specific CAs, and as cohort studies can only detect considerable increases in the risk of specific defects, most cohort studies are limited in their ability to provide assurance of safety. When we examined the distribution of specific types of CAs after paternal use of SCS, we did not, however, reveal any alarming patterns in types of CAs.
A previous study of SCS use by men in Norway (based on 1477 prednisolone-exposed fathers) suggested an OR of any birth defect of 1.2 (95% CI: 0.9-1.5) [2] . Although this study is reassuring, our current study was over a longer period of time, had distinct categories of corticosteroid 'users' and had a larger number of fathers who filled prescriptions for corticosteroids prior to conception. The effect of SCS on spermatozoa in infertile men has been evaluated in human case series from the 1960s, and these report the effect of dexamethasone in reducing autoantibodies against spermatozoa [28] [29] [30] . Corticosterone administered to rats has shown a reversible reduction in fertility regardless of the lack of adverse effects on sperm motility, sperm count or microscopic features [14] . Burnell et al. [31] studied 42 matched pairs of married men and healthy controls and found that married men with Crohn's disease using steroids did not have decreased numbers of offspring compared to married healthy controls. In 23 men with chronic inflammatory bowel disease undergoing azathioprine treatment, Dejaco et al. [6] found no negative impact on semen quality with concomitant use of prednisolone. In this paper, we examine birth outcome and not fertility in men. Fertility as an outcome in human beings would be difficult to study retrospectively and would likely require a prospective register.
The strengths of this study were that (i) it was based on nationwide data that included information on all singleton children in Denmark during the study period, (ii) we had outcome information on all children, which prevents selection bias, (iii) the information on drug exposure was based on redeemed prescriptions and not on patient recall, as drug exposure based on self-reported use may lead to recall bias or under-ascertainment, (iv) we collected information on the outcome independently of the exposure, which prevents information bias, (v) we were able to take into consideration a range ) and maternal smoking in pregnancy (yes/no). 2 A total of eight of 2380 (0.34%) in the exposed group and had missing data on birthweight and/or gestational age.
of confounders in our analyses, and finally, (vi) we used Danish health registries with high validity. The information we used from the MBR has been shown to have a high validity [24, 27, 28] . Moreover, the external validity of our study is considered good and applicable to other populations.
In our study, we had access to a complete nationwide prescription database, ensuring that all fathers could be classified according to the possible prescriptions for SCS prior to conception, and the data in the prescription database are of high quality as a result of direct computerized transfer of information when a prescribed drug is dispensed at a pharmacy [25] . Even so, the prescription data were limited by being a proxy for use of SCS. Potential misclassification of exposure due to patient non-compliance would, however, be non-differential and tend to underestimate our risk estimates, and our analyses based on patients who redeemed two or more prescriptions in the period within 3 months prior to conception strengthen the validity of our conclusions. We did not have data on abortions in our data set, and if SCS exerts an increased risk of spontaneous abortion, we might have overlooked such a potential harmful effect of SCS.
We were not able to take into consideration a possible influence of type of underlying paternal disease. This was due to the fact that the NPR only includes diagnostic codes for patients admitted to hospitals, and for a large proportion of children (45.2%), we could not classify the underlying paternal disease because the prescription of SCS derived from the general practitioners, and we had no access to data from the general practitioner. Furthermore, the many types of paternal underlying diseases did not allow us to do stratified analyses because the number within groups would have been too limited, and we could not adjust for the many co-medication opportunities for different subgroups of fathers. In addition, we were unable to evaluate an exact dose effect of SCS. From the NPD, we could extract information on the prescribed dosage, but could not relate this amount to the number of milligrams prescribed per day or to the length of treatment. We had only little information on the fathers and we cannot rule out residual confounding of father characteristics such as BMI and smoking, but an impact of a potential residual confounding would have to have a conservative effect on the results. Also, our data set does not include information on maternal drug exposure and co-morbidity, but we have no reason to believe that such factors would be unequally distributed between exposed and unexposed fathers. A possible mismatch between who is registered as father to the child in the MBR and the true biological father of the child is a bias in this type of studies. However, we expect this mismatch to be less the 3% in our cohorts [32] .
We found no increased risk of CAs, pre-term birth or SGA in the children of fathers who redeemed only one prescription of SCS within the 3-month period prior to conception. For those children fathered by men who had redeemed two or more prescriptions of SCS, we found an increased risk of CAs, although this was not statistically significant. This study, based on nationwide data, has the largest number of exposed fathers to date and provides important and overall reassuring results for paternal use of SCS prior to conception. Our results will hopefully be helpful when counselling fathers and couples with questions on the reproductive safety of SCS. 
